HUP9802286A2 - Stabilizált gyógyszerkészítmény amely valamely növekedési hormont és legalább egy bázikus aminosavmaradékot és legalább egy savas aminosav maradékot tartalmazó peptidet foglal magában - Google Patents

Stabilizált gyógyszerkészítmény amely valamely növekedési hormont és legalább egy bázikus aminosavmaradékot és legalább egy savas aminosav maradékot tartalmazó peptidet foglal magában

Info

Publication number
HUP9802286A2
HUP9802286A2 HU9802286A HUP9802286A HUP9802286A2 HU P9802286 A2 HUP9802286 A2 HU P9802286A2 HU 9802286 A HU9802286 A HU 9802286A HU P9802286 A HUP9802286 A HU P9802286A HU P9802286 A2 HUP9802286 A2 HU P9802286A2
Authority
HU
Hungary
Prior art keywords
amino acid
acid residue
peptide
growth hormone
pharmaceutical formulation
Prior art date
Application number
HU9802286A
Other languages
English (en)
Inventor
Per Balschmidt
Thorkild Christensen
Ole Hvilsted Olsen
Hans Holmegaard Soerensen
Lars Thim
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of HUP9802286A2 publication Critical patent/HUP9802286A2/hu
Publication of HUP9802286A3 publication Critical patent/HUP9802286A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány tárgya gyógyszerkészítmény, amely növekedési hőrmőnt éslegalább egy bázikűs aminősav maradékőt és leglaább egy savas aminősavmaradékőt magába főglaló peptidet tartalmaz additívűmként vagypűfferőldóanyagként és nagy stabilitást műtató dezamidálással,őxidációval és a peptikötés bőntásával szemben. A termék stabilitásalehetővé teszi annak raktárőzását és szállítását liőfilizáltállapőtban, őldőtt vagy újraőldőtt főrmában, szőbahőmérsékleten. ŕ
HU9802286A 1995-07-12 1996-06-28 A stabilized pharmaceutical formulation comprising a growth hormone and a peptide comprising at least, one basic amino acid residue and at least one acid amino acid residue HUP9802286A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88195P 1995-07-12 1995-07-12

Publications (2)

Publication Number Publication Date
HUP9802286A2 true HUP9802286A2 (hu) 1999-02-01
HUP9802286A3 HUP9802286A3 (en) 1999-06-28

Family

ID=21693419

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9802286A HUP9802286A3 (en) 1995-07-12 1996-06-28 A stabilized pharmaceutical formulation comprising a growth hormone and a peptide comprising at least, one basic amino acid residue and at least one acid amino acid residue

Country Status (14)

Country Link
EP (1) EP0837690A1 (hu)
JP (1) JPH11510483A (hu)
KR (1) KR19990028908A (hu)
CN (1) CN1190896A (hu)
AU (1) AU699850B2 (hu)
BR (1) BR9609573A (hu)
CA (1) CA2226553A1 (hu)
CZ (1) CZ6198A3 (hu)
HU (1) HUP9802286A3 (hu)
IL (1) IL122519A0 (hu)
NO (1) NO980103D0 (hu)
PL (1) PL324386A1 (hu)
WO (1) WO1997002833A1 (hu)
ZA (1) ZA965367B (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
AU8111301A (en) 2000-08-07 2002-02-18 Inhale Therapeutic Syst Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
AU2003289317A1 (en) * 2002-12-11 2004-06-30 Santen Pharmaceutical Co., Ltd. Preservative for ophthalmology
CN103751769B (zh) * 2013-12-25 2015-08-19 楼秀余 一种冻干重组人生长激素胶囊及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
HUT69402A (en) * 1991-12-20 1995-09-28 Novo Nordisk As Process for producing stabilized pharmaceutical formulations comprising growth hormone and histidine
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
EP0805689A1 (en) * 1995-01-13 1997-11-12 Novo Nordisk A/S A stabilized pharmaceutical formulation comprising a growth hormone and x-lys

Also Published As

Publication number Publication date
KR19990028908A (ko) 1999-04-15
CN1190896A (zh) 1998-08-19
ZA965367B (en) 1997-01-23
IL122519A0 (en) 1998-06-15
NO980103L (no) 1998-01-09
EP0837690A1 (en) 1998-04-29
NO980103D0 (no) 1998-01-09
JPH11510483A (ja) 1999-09-14
CA2226553A1 (en) 1997-01-30
HUP9802286A3 (en) 1999-06-28
MX9800309A (es) 1998-07-31
AU699850B2 (en) 1998-12-17
WO1997002833A1 (en) 1997-01-30
AU6353396A (en) 1997-02-10
CZ6198A3 (cs) 1998-06-17
PL324386A1 (en) 1998-05-25
BR9609573A (pt) 1999-03-02

Similar Documents

Publication Publication Date Title
DE69228704D1 (de) Stabilisierte pharmazeutische formulierung, die wachstumshormon und asparagin enthält
AU694229B2 (en) A pharmaceutical preparation comprising glucagon
CA2125855A1 (en) A stabilized pharmaceutical formulation comprising growth hormone and histidine
HUP9802287A2 (hu) Cinkkel és kívánt esetben lizinnel vagy kalciumionnal előkezelt növekedési hormont tartalmazó stabilizált gyógyszerkészítmény
MY128629A (en) Stabilized interleukin 2
IL109448A0 (en) Risperidone pamoate, its preparation and pharmaceutical compositions containing it
DE69525955D1 (de) Ein wachstumshormon und isoleucin enthaltende pharmazeutische formulierung
HUP0301851A2 (hu) Javított diszpergálhatóságú szárazpor-összetételek
HUP0000589A2 (hu) Vizes peptid készítmények
HUP9603237A2 (hu) (R)-(-)-2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihidro-benzizotiazol-2-il)-butil]-amino-metil}-kromán kristályos hidrokloridja, eljárás előállítására és a vegyületeket tartalmazó gyógyszerkészítmények
PT785795E (pt) Composicao farmaceutica
HUP9802286A2 (hu) Stabilizált gyógyszerkészítmény amely valamely növekedési hormont és legalább egy bázikus aminosavmaradékot és legalább egy savas aminosav maradékot tartalmazó peptidet foglal magában
WO1996022305A3 (en) Modified peptides
ITRM920349A1 (it) Composizioni farmaceutiche contenenti il-6
IL115592A (en) Stabilized pharmaceutical formulation comprising a growth hormone and leucine
SE9403389D0 (sv) Pharmaceutical composition containing derivattves of sex hormones
DE69430416D1 (de) Zusammensetzungen aus Aminosäure zur Behandlung von Infektionen
HUP9904327A2 (hu) Kinupristint és dalfopristint tartalmazó gyógyszerkészítmények és eljárás előállításukra
ATE247961T1 (de) Sufentanilhaltige arzneimittel mit verzögerter wirkstoffabgabe